Now Reading
Pfizer, BioNTech to request COVID-19 booster authorization for ages 5-11
Subscribe
Sign In

Pfizer, BioNTech to request COVID-19 booster authorization for ages 5-11

Pfizer to seek booster authorization for ages 5-11. Favorable results reported in booster study for kids.

Where: United States

The Facts

On Thursday, Pfizer and BioNTech released Phase 2/3 clinical trial data, revealing a high immune response in children aged 5-11 against COVID-19 after receiving a booster dose of the Pfizer-BioNTech vaccine.
The clinical trial oversaw the participation of 140 children in the given age group; a 6-fold increase in neutralizing antibodies against the SARS-CoV-2 wild-type strain was found in the children after they received the booster dose.
Furthermore, a subanalysis of 30 samples showed a 36-fold increase in Omicron-neutralizing antibodies following a booster dose. Pfizer stated, “A robust response was observed regardless of prior SARS-CoV-2 infection.”
The two companies will now submit the study’s data to the FDA to seek emergency use authorization, thus allowing ages 5-11 to receive a Pfizer-BioNTech COVID-19 booster dose.
The CDC currently recommends individuals aged 12 and older get a COVID-19 booster dose at least five months after completing their primary vaccination series. As it stands in the US, ages 12-17 can only receive a Pfizer-BioNTech COVID-19 vaccine booster.

Primary Sources

Direct, authoritative source material on this story.

Reference Articles

Articles Citable has ingested related to this story.

Reference Articles

Articles Citable has ingested related to this story.

Media Coverage

Why did we include this story

Most covered story by the media today

of articles referenced this story

Coverage by Media Outlet

Media outlets covering this story along with their positive or negative sentiment toward this story.

© 2021 Citable. All Rights Reserved.